Quantcast

Latest Antiretroviral drug Stories

2014-09-17 08:28:44

New Treatment Option Combining Protease Inhibitor and Boosting Agent Reduces the Number of Pills Required to Manage HIV TORONTO, Sept. 17, 2014 /CNW/ - Janssen Inc. announced today that PREZCOBIX(TM) (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada.(1) It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet. "We...

2014-09-16 12:31:01

Study finds HIV medication specialist improved care, lowered costs ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire-USNewswire/ -- A recent study conducted by a team of researchers from Kaiser Permanente's Mid-Atlantic Region found that the introduction of an HIV clinical pharmacist improved medication adherence, resulting in better health outcomes and lower costs for HIV positive patients. The study states that non-adherence to antiretroviral therapy (ART) has been associated with...

2014-09-15 08:28:17

PITTSBURGH and HYDERABAD, India, Sept. 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Sofosbuvir is marketed by Gilead under the brand name Sovaldi®....

2014-09-08 08:29:30

Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another RICHMOND, Calif., Sept. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating that a single infusion of Sangamo's novel ZFP Therapeutic(®), SB-728-T, resulted in sustained reduction and control of viral load (VL) in the absence of antiretroviral drugs...

2014-08-25 08:28:30

Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information. Please click: http://www.multivu.com/players/English/7197331-viiv-healthcare-vhc-triumeq-fda-approval LONDON, Aug. 25, 2014 /PRNewswire/ -- On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...

2014-08-22 23:02:13

New research report “Global HIV Infection Drug Market & Pipeline Insight” worked out by Kuick Research is now available at MarketPublishers.com. London, UK (PRWEB) August 22, 2014 The improved access to antiretroviral drugs and treatments in the recent past, specifically in the developing world, has led to the decline in the rate of HIV infection and the number of deaths due to AIDS globally. However, despite the fact that HIV infection rates are declining, the number of new...

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-08-19 08:29:32

VANCOUVER, Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with...

2014-08-05 16:27:17

A man infected by HIV-1 in 1998 was treated at the time of acute infection with 4 antiretrovirals during 2 years and is now still in remission TOULON, France, Aug. 5, 2014 /PRNewswire/ -- There is only one man cured from HIV in the world, the "Berlin" patient: the only case of HIV cure, because in every infected patient we observe a HIV persistence. To reach this cure he received a non-scalable procedure with bone marrow transplant due to acute leukemia from a special donor. His life...

2014-08-05 11:54:33

BMJ-British Medical Journal Antiretroviral drugs and chronic immune system suppression might explain link HIV infection is linked to a significantly lower risk of developing multiple sclerosis (MS), indicates observational research published online in the Journal of Neurology Neurosurgery & Psychiatry. Chronic dampening down of the immune system as a result of the infection and/or the antiretroviral drugs used to treat it might explain this association, say the researchers....


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related